US Dietary Supplement Labeling Rules and the Possibility of Medical Cost Reduction

被引:5
作者
Amagase, Harunobu [1 ]
机构
[1] Amer Chamber Commerce Japan, Tokyo 1060041, Japan
关键词
dietary supplements; health foods; US labeling system; BETA(3)-ADRENERGIC-RECEPTOR GENE;
D O I
10.3177/jnsv.61.S136
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
US dietary supplements classified as foods are regulated under the Dietary Supplement Health and Education Act (DSHEA) and other rules. After the DSHEA established in 1994, the supplement market grew by about 4 times and reached $32 billion as of 2012. One of the major reasons for this market expansion is that consumers can recognize functions of the supplements by the structure/function (S/F) claims. S/F claims must not be false or misleading, and must be based upon reliable scientific evidence, especially clinical studies. At the same time, disclaimers must be shown on the package, which are "These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure or prevent any disease." Both the FDA and Federal Trade Commission (FTC) are responsible for label claims and advertisement of dietary supplements. S/F claims are not medical claims, but these may have impact on people's mindset to be healthier. Recent research shows utilizing dietary supplements in 4 major areas with 10 popular ingredients could hypothetically reduce medical costs by over $50 billion in the US in the period of 2013-2020. Predicted fewer health problems and reduced medical cost information will further increase awareness of supplement usage and thus may raise quality of life. These may reduce the medical cost significantly, if the products are used appropriately with sufficient consumer education.
引用
收藏
页码:S136 / S138
页数:3
相关论文
共 5 条
[1]   Why US Adults Use Dietary Supplements [J].
Bailey, Regan L. ;
Gahche, Jaime J. ;
Miller, Paige E. ;
Thomas, Paul R. ;
Dwyer, Johanna T. .
JAMA INTERNAL MEDICINE, 2013, 173 (05) :355-361
[2]  
United States. Government Accountability Office, 2013, DIETARY SUPPLEMENTS, V7, P1427
[3]   TIME OF ONSET OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE [J].
WALSTON, J ;
SILVER, K ;
BOGARDUS, C ;
KNOWLER, WC ;
CELI, FS ;
AUSTIN, S ;
MANNING, B ;
STROSBERG, AD ;
STERN, MP ;
RABEN, N ;
SORKIN, JD ;
ROTH, J ;
SHULDINER, AR .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (06) :343-347
[4]   ASSOCIATION OF A POLYMORPHISM IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE WITH FEATURES OF THE INSULIN-RESISTANCE SYNDROME IN FINNS [J].
WIDEN, E ;
LEHTO, M ;
KANNINEN, T ;
WALSTON, J ;
SHULDINER, AR ;
GROOP, LC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (06) :348-351
[5]   MUTATION OF BETA(3)-ADRENEGIC-RECEPTOR GENE AND RESPONSE TO TREATMENT OF OBESITY [J].
YOSHIDA, T ;
SAKANE, N ;
UMEKAWA, T ;
SAKAI, M ;
TAKAHASHI, T ;
KONDO, M .
LANCET, 1995, 346 (8987) :1433-1434